Cite
Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018.
MLA
Amaador, Karima, et al. “Primary Therapy and Relative Survival in Patients with Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia: A Population‐based Study in the Netherlands, 1989–2018.” British Journal of Haematology, vol. 196, no. 3, Feb. 2022, pp. 660–69. EBSCOhost, https://doi.org/10.1111/bjh.17856.
APA
Amaador, K., Kersten, M. J., Visser, O., Brink, M., Posthuma, E. F. M., Minnema, M. C., Vos, J. M. I., & Dinmohamed, A. G. (2022). Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018. British Journal of Haematology, 196(3), 660–669. https://doi.org/10.1111/bjh.17856
Chicago
Amaador, Karima, Marie José Kersten, Otto Visser, Mirian Brink, Eduardus F. M. Posthuma, Monique C. Minnema, Josephine M. I. Vos, and Avinash G. Dinmohamed. 2022. “Primary Therapy and Relative Survival in Patients with Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia: A Population‐based Study in the Netherlands, 1989–2018.” British Journal of Haematology 196 (3): 660–69. doi:10.1111/bjh.17856.